193 related articles for article (PubMed ID: 16238103)
1. In vivo and in vitro estrogenic and progestagenic actions of Tibolone.
Sadarangani A; Salgado AM; Kato S; Pinto M; Carvajal A; Monso C; Owen GI; Vigil P
Biol Res; 2005; 38(2-3):245-58. PubMed ID: 16238103
[TBL] [Abstract][Full Text] [Related]
2. Molecular portrait of the progestagenic and estrogenic actions of tibolone: behavior of cellular networks in response to tibolone.
Hanifi-Moghaddam P; Gielen SC; Kloosterboer HJ; De Gooyer ME; Sijbers AM; van Gool AJ; Smid M; Moorhouse M; van Wijk FH; Burger CW; Blok LJ
J Clin Endocrinol Metab; 2005 Feb; 90(2):973-83. PubMed ID: 15572424
[TBL] [Abstract][Full Text] [Related]
3. Receptor profiling and endocrine interactions of tibolone.
de Gooyer ME; Deckers GH; Schoonen WG; Verheul HA; Kloosterboer HJ
Steroids; 2003 Jan; 68(1):21-30. PubMed ID: 12475720
[TBL] [Abstract][Full Text] [Related]
4. Progestagenic effects of tibolone are target gene-specific in human endometrial cells.
Zhang W; Mazella J; Kloosterboer HJ; Tseng L
J Soc Gynecol Investig; 2006 Sep; 13(6):459-65. PubMed ID: 16879988
[TBL] [Abstract][Full Text] [Related]
5. Transvaginal ultrasonographic assessment of the endometrium in asymptomatic, postmenopausal women using different HRT regimens containing tibolone or estrogen.
Kurtay G; Berker B; Demirel C
J Reprod Med; 2004 Nov; 49(11):893-8. PubMed ID: 15603100
[TBL] [Abstract][Full Text] [Related]
6. The hormone replacement therapy drug tibolone acts very similar to medroxyprogesterone acetate in an estrogen-and progesterone-responsive endometrial cancer cell line.
Hanifi-Moghaddam P; Sijmons B; Ott MC; van Ijcken WF; Nowzari D; Kuhne EC; van der Spek P; Kloosterboer HJ; Burger CW; Blok LJ
J Mol Endocrinol; 2006 Dec; 37(3):405-13. PubMed ID: 17170081
[TBL] [Abstract][Full Text] [Related]
7. Effects of tibolone and its metabolites on Angiopoietin-1, Tie-2 and tumor necrosis factor-alpha mRNA in Ishikawa cells. Implication for tibolone's effects on the endometrium.
Mirkin S; Archer DF
Maturitas; 2007 Aug; 57(4):338-46. PubMed ID: 17478063
[TBL] [Abstract][Full Text] [Related]
8. Effects of tibolone and its metabolites on prolactin and insulin-like growth factor binding protein-1 expression in human endometrial stromal cells.
Guzel E; Buchwalder L; Basar M; Kayisli U; Ocak N; Bozkurt I; Lockwood CJ; Schatz F
Gynecol Endocrinol; 2015 May; 31(5):414-8. PubMed ID: 25856298
[TBL] [Abstract][Full Text] [Related]
9. Progestin effects on cell proliferation pathways in the postmenopausal mammary gland.
Wood CE; Branstetter D; Jacob AP; Cline JM; Register TC; Rohrbach K; Huang LY; Borgerink H; Dougall WC
Breast Cancer Res; 2013; 15(4):R62. PubMed ID: 23938070
[TBL] [Abstract][Full Text] [Related]
10. Tibolone and metabolites induce prolactin production in human endometrial stromal cells in vitro: evidence for cell-specific metabolism.
Groothuis PG; De Gooyer ME; ten Kate J; Menheere PP; Dunselman GA; de Goeij AF; Verbost P; Ederveen AG; Kloosterboer HJ
J Steroid Biochem Mol Biol; 2006 Aug; 100(4-5):152-60. PubMed ID: 16781141
[TBL] [Abstract][Full Text] [Related]
11. Endometrial assessment in women using tibolone or placebo: 1-year randomized trial and 2-year observational study.
Wender MC; Edelweiss MI; Campos LS; de Castro JA; Spritzer PM
Menopause; 2004; 11(4):423-9. PubMed ID: 15243280
[TBL] [Abstract][Full Text] [Related]
12. Progestogenic effects of tibolone on human endometrial cancer cells.
Blok LJ; De Ruiter PE; Kühne EC; Hanekamp EE; Grootegoed JA; Smid-Koopman E; Gielen SC; De Gooyer ME; Kloosterboer HJ; Burger CW
J Clin Endocrinol Metab; 2003 May; 88(5):2327-34. PubMed ID: 12727992
[TBL] [Abstract][Full Text] [Related]
13. Histological and immunohistochemical evaluation of postmenopausal endometrium after 3 weeks of treatment with tibolone, estrogen only, or estrogen plus progestagen.
Klaassens AH; van Wijk FH; Hanifi-Moghaddam P; Sijmons B; Ewing PC; Ten Kate-Booij MJ; Kooi GS; Kloosterboer HJ; Blok LJ; Burger CW
Fertil Steril; 2006 Aug; 86(2):352-61. PubMed ID: 16828477
[TBL] [Abstract][Full Text] [Related]
14. Regulation of SULT1E1 expression in Ishikawa adenocarcinoma cells by tibolone.
Falany JL; Falany CN
Steroids; 2006 Oct; 71(10):880-5. PubMed ID: 16857224
[TBL] [Abstract][Full Text] [Related]
15. Tibolone and risk of gynecological hormone sensitive cancer.
Løkkegaard ECL; Mørch LS
Int J Cancer; 2018 Jun; 142(12):2435-2440. PubMed ID: 29349823
[TBL] [Abstract][Full Text] [Related]
16. Effects of tibolone metabolites on human endometrial cell lines in co-culture.
Barbier C; Kloosterboer HJ; Kaufman DG
Reprod Sci; 2008 Jan; 15(1):75-82. PubMed ID: 18212357
[TBL] [Abstract][Full Text] [Related]
17. Effect of tibolone (Org OD14) and its metabolites on aromatase and estrone sulfatase activity in human breast adipose stromal cells and in MCF-7 and T47D breast cancer cells.
van de Ven J; Donker GH; Sprong M; Blankenstein MA; Thijssen JH
J Steroid Biochem Mol Biol; 2002 Jul; 81(3):237-47. PubMed ID: 12163135
[TBL] [Abstract][Full Text] [Related]
18. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
Langer RD; Landgren BM; Rymer J; Helmond FA;
Am J Obstet Gynecol; 2006 Nov; 195(5):1320-7. PubMed ID: 16875644
[TBL] [Abstract][Full Text] [Related]
19. Effects of low dose of tibolone on steroid receptors and Bcl-2 on the postmenopausal endometrium.
Reis BF; Lima SM; Silva GM; Francisco AM; Barbosa LC; Archangelo SC; Grande RM
Histol Histopathol; 2016 Jun; 31(6):629-34. PubMed ID: 26670665
[TBL] [Abstract][Full Text] [Related]
20. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/-progestogen) treatments.
Kloosterboer HJ; Ederveen AG
J Steroid Biochem Mol Biol; 2002 Dec; 83(1-5):157-65. PubMed ID: 12650712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
